Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial

J Am Acad Dermatol. 2005 Nov;53(5):887-9. doi: 10.1016/j.jaad.2005.06.053.


In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Double-Blind Method
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Psoriasis / drug therapy*
  • Quality of Life*
  • Receptors, Tumor Necrosis Factor / therapeutic use*


  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Etanercept